Redeye comments on Xvivos acquisition and financing of Organ Assist B.V. We have, given the deal announced yesterday, factored in the new complementary business acquired and the opportunities it brings. We have also increased our estimates from 2021 and forward based on a somewhat more positive short - term view regarding the Covid-19 effects as we advance. We raise our fair value range to SEK 130 – 310 per share with a base case of SEK 235 (195) per share.